ACM
IOVA icon

Arcataur Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Arcataur Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Buy
27,600
+2,000
+8% +$7.6K 0.03% 105
2026
Q1 		$89.9K Buy
25,600
+15,000
+142% +$48K 0.03% 103
2025
Q4 		$28.9K Buy
+10,600
New +$24.5K 0.01% 103

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
OIC
Orion Investment Company St. Louis, Missouri $343M AUM 52.59% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Arcataur Capital Management's IOVA Position: Q2 2026 in Review

Arcataur Capital Management increased its Iovance Biotherapeutics (IOVA) stake by 7.8% in Q2 2026, buying an estimated $7.6K and bringing the position to 27,600 shares worth $115K. The position accounts for 0.03% of the portfolio, ranked #105.

Arcataur Capital Management first reported a position in IOVA in Q4 2025 and has held it in 3 quarters since. 171 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Arcataur Capital Management held 27,600 shares of Iovance Biotherapeutics worth $115K as of Q2 2026.
  • Arcataur Capital Management bought 2,000 Iovance Biotherapeutics shares in Q2 2026, an estimated $7.6K.
  • Iovance Biotherapeutics made up 0.03% of Arcataur Capital Management's portfolio in Q2 2026, its #105 holding.
  • Arcataur Capital Management first reported a position in Iovance Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 171 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Arcataur Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.